R Winn

2.3k total citations · 1 hit paper
19 papers, 1.8k citations indexed

About

R Winn is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, R Winn has authored 19 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in R Winn's work include Cancer Treatment and Pharmacology (6 papers), Colorectal Cancer Treatments and Studies (4 papers) and Global Cancer Incidence and Screening (2 papers). R Winn is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Colorectal Cancer Treatments and Studies (4 papers) and Global Cancer Incidence and Screening (2 papers). R Winn collaborates with scholars based in United States and Puerto Rico. R Winn's co-authors include Waun Ki Hong, Christopher E. Desch, Robert C. Bast, J. Milburn Jessup, Gershon Y. Locker, Sheila E. Taube, Larry Norton, Robert Mennel, Nancy E. Kemeny and Peter M. Ravdin and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

R Winn

19 papers receiving 1.7k citations

Hit Papers

Tumor Marker Utility Grading System: a Framework to Evalu... 1996 2026 2006 2016 1996 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers
    1996 553 citations D. F. Hayes, Robert C. Bast et al. JNCI Journal of the National Cancer Institute profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R Winn United States 14 1.0k 565 505 406 170 19 1.8k
Ronald S. Walters United States 29 1.5k 1.5× 757 1.3× 273 0.5× 466 1.1× 216 1.3× 75 3.5k
Franca Lucchini Italy 30 1.3k 1.3× 409 0.7× 550 1.1× 308 0.8× 384 2.3× 53 2.9k
N Stuart United Kingdom 18 744 0.7× 781 1.4× 232 0.5× 503 1.2× 141 0.8× 36 1.9k
Erdem Göker Türkiye 25 1.1k 1.1× 752 1.3× 932 1.8× 256 0.6× 139 0.8× 99 2.5k
Teresa Gamucci Italy 28 2.3k 2.3× 827 1.5× 688 1.4× 723 1.8× 155 0.9× 128 3.5k
Jamey Skillings Canada 18 1.3k 1.2× 281 0.5× 514 1.0× 260 0.6× 311 1.8× 40 2.1k
John F. Sandbach United States 15 1.5k 1.4× 661 1.2× 360 0.7× 864 2.1× 214 1.3× 32 2.4k
Jean‐Paul Guastalla France 31 2.2k 2.2× 621 1.1× 495 1.0× 674 1.7× 285 1.7× 109 3.7k
T Dyba Italy 11 893 0.9× 520 0.9× 642 1.3× 356 0.9× 139 0.8× 28 2.1k
Wayne Rackoff United States 19 1.0k 1.0× 766 1.4× 945 1.9× 362 0.9× 117 0.7× 35 2.9k

Countries citing papers authored by R Winn

Since Specialization
Citations

This map shows the geographic impact of R Winn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R Winn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R Winn more than expected).

Fields of papers citing papers by R Winn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R Winn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R Winn. The network helps show where R Winn may publish in the future.

Co-authorship network of co-authors of R Winn

This figure shows the co-authorship network connecting the top 25 collaborators of R Winn. A scholar is included among the top collaborators of R Winn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R Winn. R Winn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Lippman, Scott M., J. Jack Lee, Daniel D. Karp, et al.. (2001). Randomized Phase III Intergroup Trial of Isotretinoin to Prevent Second Primary Tumors in Stage I Non-Small-Cell Lung Cancer. JNCI Journal of the National Cancer Institute. 93(8). 605–618. 213 indexed citations
2.
Millikan, Randall E., et al.. (2001). Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer. Urologic Oncology Seminars and Original Investigations. 6(3). 111–115. 51 indexed citations
3.
Wu, Xifeng, Jun Gu, Waun Ki Hong, et al.. (1998). Benzo[a]pyrene Diol Epoxide and Bleomycin Sensitivity and Susceptibility to Cancer of Upper Aerodigestive Tract. JNCI Journal of the National Cancer Institute. 90(18). 1393–1399. 56 indexed citations
4.
Winn, R, et al.. (1998). The NCCN guideline program--1998.. PubMed. 12(11A). 30–4. 3 indexed citations
5.
Pazdur, Richard, et al.. (1997). Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma.. Journal of Clinical Oncology. 15(8). 2905–2909. 39 indexed citations
6.
Guidry, Jeffrey J., L A Aday, Dongyu Zhang, & R Winn. (1997). Transportation as a barrier to cancer treatment.. PubMed. 5(6). 361–6. 163 indexed citations
7.
Hayes, D. F., Robert C. Bast, Christopher E. Desch, et al.. (1996). Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers. JNCI Journal of the National Cancer Institute. 88(20). 1456–1466. 553 indexed citations breakdown →
8.
Bennett, Charles L., Thomas J. Smith, John Weeks, et al.. (1996). Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology.. Journal of Clinical Oncology. 14(9). 2511–2520. 54 indexed citations
9.
Winn, R, et al.. (1996). The NCCN Guidelines Development Program.. PubMed. 10(11 Suppl). 23–8. 13 indexed citations
10.
11.
Huber, Martin H., Scott M. Lippman, Steven E. Benner, et al.. (1995). Phase II study of carboplatin and continuous infusion bleomycin followed by cisplatin and 5-fluorouracil in recurrent head and neck cancer. Annals of Oncology. 6(1). 83–85. 1 indexed citations
12.
Murphy, William K., Frank V. Fossella, R Winn, et al.. (1993). Phase II Study of Taxol in Patients With Untreated Advanced Non-Small-Cell Lung Cancer. JNCI Journal of the National Cancer Institute. 85(5). 384–388. 373 indexed citations
13.
Benner, Steven E., R Winn, Scott M. Lippman, et al.. (1993). Regression of Oral Leukoplakia With  -Tocopherol: A Community Clinical Oncology Program Chemoprevention Study. JNCI Journal of the National Cancer Institute. 85(1). 44–47. 111 indexed citations
14.
Pazdur, Richard, et al.. (1992). Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer.. American Journal of Clinical Oncology. 15(6). 524–7. 15 indexed citations
15.
Dimery, Isaiah W., Burke J. Brooks, R Winn, et al.. (1991). Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.. Journal of Clinical Oncology. 9(11). 1939–1944. 10 indexed citations
16.
Pazdur, Richard, Jaffer A. Ajani, Yehuda Z. Patt, et al.. (1990). Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma.. Journal of Clinical Oncology. 8(12). 2027–2031. 121 indexed citations
17.
Vogel, Victor G., et al.. (1990). Breast screening compliance following a statewide low-cost mammography project.. PubMed. 14(5). 573–6. 8 indexed citations
18.
Einzig, Avi I., D. P. Kelsen, Edgar Cheng, et al.. (1985). Phase II trial of carboplatin in patients with adenocarcinomas of the upper gastrointestinal tract.. PubMed. 69(12). 1453–4. 13 indexed citations
19.
Winn, R, et al.. (1969). Pneumatization of the temporal bone in children with cleft palate.. PubMed. 6. 154–9. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ronald S. Walters Breakdown of academic impact, for papers by Franca Lucchini Breakdown of academic impact, for papers by N Stuart Breakdown of academic impact, for papers by Erdem Göker Breakdown of academic impact, for papers by Teresa Gamucci Breakdown of academic impact, for papers by Jamey Skillings Breakdown of academic impact, for papers by John F. Sandbach Breakdown of academic impact, for papers by Jean‐Paul Guastalla Breakdown of academic impact, for papers by T Dyba Breakdown of academic impact, for papers by Wayne Rackoff
Rankless by CCL
2026